Pharmaceuticals company Ami Organics announced Q2FY25 results Revenue from operations for Q2FY25 grew by 43.2% YoY to Rs 2,467 million. The gross margin for the quarter improved to 43.4% up 239 bps YoY and 136 bps QoQ EBITDA for the quarter came at Rs 489 million up 97.2% YoY compared to Rs 248 million in Q2FY24. EBITDA margin for the quarter was at 19.8% as compared to 14.4% in Q2FY24. PAT for the quarter was Rs 375 million up 155% as compared to adjusted PAT of Rs 147 million in Q2FY24. The PAT margin for the quarter was at 15.2% up 668 bps YoY and 682 bps QoQ. Export at 76%; domestic business at 24%. Further to the inspection concluded by by Pharmaceutical and Medical Devices Agency, Japan (“PMDA”) without any critical/major observation, the agency has issued Inspection Result Report declaring the Sachin Facility as a Good Manufacturing Practices (GMP) compliant. Naresh Patel, Executive Chairman & Managing Director, Ami Organics, said: “Despite ongoing challenges in the global chemical industry, I am pleased to report stellar year-over-year growth of 43.2% in Q2FY25, driven by exceptional performance in our Pharmaceutical Intermediates and Specialty Chemicals businesses. Our key products maintained growth momentum, and an earlier-than-anticipated ramp-up in our CDMO business provided an additional boost to our results. I am also proud to announce that PMDA Japan has issued an Inspection Result Report declaring our Sachin Facility as Good Manufacturing Practices (GMP) compliant. We are experiencing a resurgence in demand for our core molecules, bolstered by ramp up in CDMO contract and strong volume growth within our Specialty Chemicals division. Based on the current order pipeline, we are raising our revenue growth guidance for FY25 from 25% to 30%.” Result PDF
Pharmaceuticals company Ami Organics announced Q1FY25 results: Revenue from operations for Q1FY25 grew by 14.9% YoY to Rs 1,767 million The gross margin for the quarter was at 42.1%. EBITDA for the quarter came at Rs 295 million down 13.2% YoY compared to Rs 340 million in Q1FY24. EBITDA margin for the quarter was at 16.7% as compared to 22.1% in Q1FY24. EBITDA margins contracted due to lower gross margins coupled with higher employee expenses led by annual increments as well as new hiring for Ankleshwar plant. PAT for the quarter was Rs 147 million. PAT margin for the quarter was 8.3%. PAT margins were impacted due to higher finance cost as well as higher depreciation cost. Commenting on results, Naresh Patel, Executive Chairman & Managing Director, Ami Organics, said: “I am pleased to report that we continue to successfully navigate the challenging industry landscape, achieving strong revenue of ?176 crore, which represents a 14.9% year-over-year growth. This growth was primarily driven by our core pharmaceutical business, while the specialty chemicals segment saw a modest 10% increase. During the quarter, we also successfully completed the Good Manufacturing Practices (GMP) inspection by the Pharmaceutical and Medical Devices Agency (PMDA), Japan, with no critical or major observations. To our knowledge, we may be the only company in India to have successfully passed both USFDA and PMDA inspections in the advanced pharmaceutical intermediate sector. Historically, Q1 is always lowest quarter in terms of revenue each financial year since inception, and we typically see sequential growth from Q1 to Q4. I anticipate similar strong sequential growth in the coming quarters. Looking at our current order book, I am confident that we will comfortably meet our 25% growth guidance for the year.” Result PDF